258 related articles for article (PubMed ID: 9743946)
1. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
5. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
van der Gaast A; Vlastuin M; Kok TC; Splinter TA
Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
7. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
Mross K; Bewermeier P; Reifke J; Krüger W; Stockschläder M; Zander A; Hossfeld DK
Bone Marrow Transplant; 1994 Apr; 13(4):423-30. PubMed ID: 8019466
[TBL] [Abstract][Full Text] [Related]
10. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
Würthwein G; Boos J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
[TBL] [Abstract][Full Text] [Related]
11. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.
Fleischhack G; Reif S; Hasan C; Jaehde U; Hettmer S; Bode U
Br J Cancer; 2001 Jun; 84(11):1453-9. PubMed ID: 11384092
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
14. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
15. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the variability of etoposide pharmacokinetics in children.
Boos J; Real E; Schulze-Westhof ; Wolff J; Euting T; Jürgens H
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):495-7. PubMed ID: 1490803
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
19. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
20. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]